BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012;12:50. [PMID: 22292935 DOI: 10.1186/1471-2407-12-50] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Baniak N, Senger JL, Ahmed S, Kanthan SC, Kanthan R. Gastric biomarkers: a global review. World J Surg Oncol. 2016;14:212. [PMID: 27514667 DOI: 10.1186/s12957-016-0969-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
2 Kim HJ, Lee SY, Oh SC. The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. Front Physiol. 2016;7:168. [PMID: 27242542 DOI: 10.3389/fphys.2016.00168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
3 Pai SM, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. Front Oncol 2021;11:632609. [PMID: 34168977 DOI: 10.3389/fonc.2021.632609] [Reference Citation Analysis]
4 Lee H, Lee JH, Kim DK, Choi IJ, Hwang I, Kang YN, Kim S. PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation. Int J Med Sci 2015;12:349-53. [PMID: 26019684 DOI: 10.7150/ijms.11281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS 2013;121:954-66. [DOI: 10.1111/apm.12152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Basu M, Chakraborty B, Ghosh S, Samadder S, Dutta S, Roy A, Pal DK, Ghosh A, Panda CK. Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma. Mutagenesis 2020;35:499-508. [DOI: 10.1093/mutage/geaa031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Makii C, Ikeda Y, Oda K, Uehara Y, Nishijima A, Koso T, Kawata Y, Kashiyama T, Miyasaka A, Sone K, Tanikawa M, Tsuruga T, Mori-Uchino M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Kawana K, Hasegawa K, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. Gynecol Oncol 2019;155:331-9. [PMID: 31493899 DOI: 10.1016/j.ygyno.2019.08.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Kim K, Lee HW. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. Appl Immunohistochem Mol Morphol 2018;26:740-8. [PMID: 28549032 DOI: 10.1097/PAI.0000000000000524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Matsuoka T, Yashiro M. The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 2014;6:1441-1463. [PMID: 25003395 DOI: 10.3390/cancers6031441] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 12.0] [Reference Citation Analysis]
10 Dang S, Qu Y, Wei J, Shao Y, Yang Q, Ji M, Shi B, Hou P. Low copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in early-stage laryngeal cancer patients. Diagn Pathol 2014;9:28. [PMID: 24499477 DOI: 10.1186/1746-1596-9-28] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
11 Camilo V, Barros R, Celestino R, Castro P, Vieira J, Teixeira MR, Carneiro F, Pinto-de-Sousa J, David L, Almeida R. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer 2014;14:753. [PMID: 25300947 DOI: 10.1186/1471-2407-14-753] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
12 Carlomagno N, Incollingo P, Tammaro V, Peluso G, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G, Pisani A, Riccio E, Sabbatini M, Bracale UM, Calogero A, Dodaro CA, Santangelo M. Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Res Int. 2017;2017:7869802. [PMID: 29094049 DOI: 10.1155/2017/7869802] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
13 Saha SK, Islam SMR, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer. J Clin Med 2019;8:E355. [PMID: 30871151 DOI: 10.3390/jcm8030355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
14 Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161. [PMID: 23232172 DOI: 10.1186/1741-7015-10-161] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
15 Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q, Shi B, Ji M, Hou P. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis 2016;7:e2442. [PMID: 27787520 DOI: 10.1038/cddis.2016.346] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
16 Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35:1475-1482. [PMID: 26073079 DOI: 10.1038/onc.2015.209] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
17 Velho S, Fernandes MS, Leite M, Figueiredo C, Seruca R. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol 2014; 20(44): 16433-16442 [PMID: 25469011 DOI: 10.3748/wjg.v20.i44.16433] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
18 Joutei HAH, Marchoudi N, Mahfoud W, Sadaoui I, Fechtali T, Benomar H. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients. Arab J Gastroenterol 2018;19:155-8. [PMID: 30503528 DOI: 10.1016/j.ajg.2018.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Cui W, Cai Y, Zhou X. Advances in subunits of PI3K class I in cancer. Pathology. 2014;46:169-176. [PMID: 24614719 DOI: 10.1097/pat.0000000000000066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Sabbah DA, Vennerstrom JL, Zhong HA. Binding Selectivity Studies of Phosphoinositide 3-Kinases Using Free Energy Calculations. J Chem Inf Model 2012;52:3213-24. [DOI: 10.1021/ci3003057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
21 Shi J, Qu YP, Hou P. Pathogenetic mechanisms in gastric cancer. World J Gastroenterol 2014; 20(38): 13804-13819 [PMID: 25320518 DOI: 10.3748/wjg.v20.i38.13804] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
22 Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q, Hou P. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene 2019;38:4804-19. [PMID: 30804458 DOI: 10.1038/s41388-019-0759-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
23 Yang Q, Shao Y, Shi J, Qu Y, Wu K, Dang S, Shi B, Hou P. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clin Biochem. 2014;47:111-116. [PMID: 24505629 DOI: 10.1016/j.clinbiochem.2013.10.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Essakly A, Loeser H, Kraemer M, Alakus H, Chon SH, Zander T, Buettner R, Hillmer AM, Bruns CJ, Schroeder W, Gebauer F, Quaas A. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. Transl Oncol 2020;13:157-64. [PMID: 31865178 DOI: 10.1016/j.tranon.2019.10.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
25 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Su C, Li D, Li N, Du Y, Yang C, Bai Y, Lin C, Li X, Zhang Y. Studying the mechanism of PLAGL2 overexpression and its carcinogenic characteristics based on 3'-untranslated region in colorectal cancer. Int J Oncol. 2018;. [PMID: 29512763 DOI: 10.3892/ijo.2018.4305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
27 Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Res 2019;21:39. [PMID: 30867034 DOI: 10.1186/s13058-019-1115-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
28 Zheng S, Yang C, Lu M, Liu Q, Liu T, Dai F, Gao X, Sheyhidin I, Lu X. PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma. Hum Pathol 2016;53:121-9. [PMID: 27001433 DOI: 10.1016/j.humpath.2015.11.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn SH, Park DJ, Kim HH, Lee KW. PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget. 2017;8:90948-90958. [PMID: 29207615 DOI: 10.18632/oncotarget.18770] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
30 Zhang A, Lakshmanan J, Motameni A, Harbrecht BG. MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling. Mol Cell Biochem 2018;441:89-98. [PMID: 28887744 DOI: 10.1007/s11010-017-3176-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
31 Zhang N, Yu Z, Yang X, Zhou Y, Wang J, Zhang S, Wang M, He Y. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors. European Journal of Medicinal Chemistry 2018;158:707-19. [DOI: 10.1016/j.ejmech.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Tao K, Yin Y, Shen Q, Chen Y, Li R, Chang W, Bai J, Liu W, Shi L, Zhang P. Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomed Rep 2016;4:365-8. [PMID: 26998277 DOI: 10.3892/br.2016.594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
33 Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol 2021;898:173983. [PMID: 33647255 DOI: 10.1016/j.ejphar.2021.173983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Lee J, Kim KM, Kang WK, Ou SH. Innovative personalized medicine in gastric cancer: time to move forward. Clin Genet 2014;86:37-43. [PMID: 24749947 DOI: 10.1111/cge.12408] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
35 Li H, Tian Z, Zhang Y, Yang Q, Shi B, Hou P, Ji M. Increased copy number of mitochondrial DNA predicts poor prognosis of esophageal squamous cell carcinoma. Oncol Lett 2018;15:1014-20. [PMID: 29422970 DOI: 10.3892/ol.2017.7416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Deng J, Liang H, Ying G, Dong Q, Zhang R, Yu J, Fan D, Hao X. Poor survival is associated with the methylated degree of zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer. Oncotarget 2015;6:4482-95. [PMID: 25714013 DOI: 10.18632/oncotarget.2916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
37 Smith JC, Sheltzer JM. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. Elife 2018;7:e39217. [PMID: 30526857 DOI: 10.7554/eLife.39217] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
38 Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A. Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. Oncotarget 2015;6:26935-45. [PMID: 26334097 DOI: 10.18632/oncotarget.4775] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
39 Jiang G, Huang Z, Zhang S, Wang L. PIK3CA Gene Mutations and Amplifications in Chinese Patients With Ovarian Clear Cell Carcinoma. Cancer Investigation 2013;31:639-44. [DOI: 10.3109/07357907.2013.853075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Yang L, Hu Z, Zhu J, Liang Q, Zhou H, Li J, Fan X, Zhao Z, Pan H, Fei B. Systematic Elucidation of the Mechanism of Quercetin against Gastric Cancer via Network Pharmacology Approach. Biomed Res Int 2020;2020:3860213. [PMID: 32964029 DOI: 10.1155/2020/3860213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fu XH, Chen ZT, Wang WH, Fan XJ, Huang Y, Wu XB, Huang JL, Wang JX, Lin HJ, Tan XL, Wang L, Wang JP. KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. J Cancer. 2019;10:821-828. [PMID: 30854087 DOI: 10.7150/jca.27899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
42 Guo Y, Liu Y, Yang H, Dai N, Zhou F, Yang H, Sun W, Kong J, Yuan X, Gao S. Associations of Porphyromonas gingivalis Infection and Low Beclin1 Expression With Clinicopathological Parameters and Survival of Esophageal Squamous Cell Carcinoma Patients. Pathol Oncol Res 2021;27:1609976. [DOI: 10.3389/pore.2021.1609976] [Reference Citation Analysis]
43 Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang X, Dou R, Chen H, Liu H, Qi X. Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer. 2015;15:103. [PMID: 25884175 DOI: 10.1186/s12885-015-1109-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
44 Ding L, El Zaatari M, Merchant JL. Recapitulating Human Gastric Cancer Pathogenesis: Experimental Models of Gastric Cancer. Adv Exp Med Biol 2016;908:441-78. [PMID: 27573785 DOI: 10.1007/978-3-319-41388-4_22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yip WK, He PY, Abdullah MA, Yusoff S, Seow HF. Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma. Pathol Oncol Res 2016;22:413-9. [DOI: 10.1007/s12253-015-0007-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
46 Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics 2015;15:260-71. [PMID: 25307053 DOI: 10.1002/pmic.201400234] [Cited by in Crossref: 143] [Cited by in F6Publishing: 142] [Article Influence: 17.9] [Reference Citation Analysis]
47 Zeng Z, Fu Y, Guo D, Wu Y, Ajayi OE, Wu Q. Bacterial endosymbiont Cardinium cSfur genome sequence provides insights for understanding the symbiotic relationship in Sogatella furcifera host. BMC Genomics 2018;19:688. [PMID: 30231855 DOI: 10.1186/s12864-018-5078-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
48 Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, Xu Y, Tang L, Wang H, Liu YJ, Yin X, Ji Q, Yu DH. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med 2013;11:241. [PMID: 24088382 DOI: 10.1186/1479-5876-11-241] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
49 Wu Y, Tian S, Chen Y, Ji M, Qu Y, Hou P. miR-218 inhibits gastric tumorigenesis through regulating Bmi-1/Akt signaling pathway. Pathol Res Pract 2019;215:243-50. [PMID: 30420101 DOI: 10.1016/j.prp.2018.10.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Dueñas M, Martínez-Fernández M, García-Escudero R, Villacampa F, Marqués M, Saiz-Ladera C, Duarte J, Martínez V, Gómez MJ, Martín ML, Fernández M, Castellano D, Real FX, Rodriguez-Peralto JL, De La Rosa F, Paramio JM. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 2015;54:566-76. [PMID: 24347284 DOI: 10.1002/mc.22125] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
51 Thillai K, Lam H, Sarker D, Wells CM. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Oncotarget 2017;8:14173-91. [PMID: 27845911 DOI: 10.18632/oncotarget.13309] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
52 Segovia C, Martínez-Fernández M, Dueñas M, Rubio C, López-Calderón FF, Costa C, Saiz-Ladera C, Fernández-Grajera M, Duarte J, Muñoz HG, de la Rosa F, Villacampa F, Castellano D, Paramio JM. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget 2017;8:10531-42. [PMID: 28060766 DOI: 10.18632/oncotarget.14453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
53 Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53-65. [PMID: 23669186 DOI: 10.1016/j.cca.2013.05.002] [Cited by in Crossref: 201] [Cited by in F6Publishing: 189] [Article Influence: 22.3] [Reference Citation Analysis]
54 Arora D, Chaudhary R, Singh A. System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it. Interdiscip Sci 2019;11:125-34. [PMID: 28748401 DOI: 10.1007/s12539-017-0249-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Huang KH, Chen MH, Fang WL, Lin CH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. Cancers (Basel) 2020;12:E2318. [PMID: 32824568 DOI: 10.3390/cancers12082318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ray A, Cleary MP. The potential role of leptin in tumor invasion and metastasis. Cytokine Growth Factor Rev. 2017;38:80-97. [PMID: 29158066 DOI: 10.1016/j.cytogfr.2017.11.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
57 You W, Zhang X, Ji M, Yu Y, Chen C, Xiong Y, Liu Y, Sun Y, Tan C, Zhang H, Li J, Chen W, Li R. MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells. Int J Biol Sci 2018;14:644-53. [PMID: 29904279 DOI: 10.7150/ijbs.25272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
58 Shi J, Liu W, Sui F, Lu R, He Q, Yang Q, Lv H, Shi B, Hou P. Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer. Oncotarget 2015;6:14344-59. [PMID: 25970779 DOI: 10.18632/oncotarget.3852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
59 Abbas M, Faggian A, Sintali DN, Khan GJ, Naeem S, Shi M, Dingding C. Current and future biomarkers in gastric cancer. Biomedicine & Pharmacotherapy 2018;103:1688-700. [DOI: 10.1016/j.biopha.2018.04.178] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
60 Peterson LE, Kovyrshina T. Progression inference for somatic mutations in cancer. Heliyon 2017;3:e00277. [PMID: 28492066 DOI: 10.1016/j.heliyon.2017.e00277] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
61 Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W. Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth. Oncol Lett 2018;16:1627-33. [PMID: 30008846 DOI: 10.3892/ol.2018.8848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
62 Lee D, Kim YC, Lee KM, Yoon JK, Kim YB. MET-Amplified Intramucosal Gastric Cancer Widely Metastatic after Complete Endoscopic Submucosal Dissection. Cancer Res Treat 2015;47:120-5. [PMID: 25152190 DOI: 10.4143/crt.2013.137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Agahozo MC, Sieuwerts AM, Doebar SC, Verhoef EI, Beaufort CM, Ruigrok-ritstier K, de Weerd V, Sleddens HFBM, Dinjens WNM, Martens JWM, van Deurzen CHM. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocrine-Related Cancer 2019;26:471-82. [DOI: 10.1530/erc-19-0019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
64 Roviello G, Milani M, Gobbi A, Cappelletti MR, Zanotti L, Senti C, Bottini A, Strina C, Sigala S, Generali D. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. Clinical Breast Cancer 2016;16:e57-9. [DOI: 10.1016/j.clbc.2016.02.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
65 Park J, Lee SI, Shin S, Hong JH, Yoo HM, Kim JG. Genetic profiling of somatic alterations by Oncomine Focus Assay in Korean patients with advanced gastric cancer. Oncol Lett 2020;20:129. [PMID: 32934698 DOI: 10.3892/ol.2020.11990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Yang L, Liu W, Hu Z, Yang M, Li J, Fan X, Pan H. A Systems Pharmacology Approach for Identifying the Multiple Mechanisms of Action of the Wei Pi Xiao Decoction for the Treatment of Gastric Precancerous Lesions. Evid Based Complement Alternat Med 2019;2019:1562707. [PMID: 30854000 DOI: 10.1155/2019/1562707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 Dong M, Wang HY, Zhao XX, Chen JN, Zhang YW, Huang Y, Xue L, Li HG, Du H, Wu XY. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol. 2016;53:25-34. [PMID: 26980034 DOI: 10.1016/j.humpath.2016.02.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
68 Mclean BA, Zhabyeyev P, Pituskin E, Paterson I, Haykowsky MJ, Oudit GY. PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine. Journal of Cardiac Failure 2013;19:268-82. [DOI: 10.1016/j.cardfail.2013.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
69 Wang N, She J, Liu W, Shi J, Yang Q, Shi B, Hou P. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients. Cell Cycle 2015;14:732-43. [PMID: 25590580 DOI: 10.1080/15384101.2014.998047] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
70 Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 2021:S1044-579X(21)00188-7. [PMID: 34175443 DOI: 10.1016/j.semcancer.2021.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Fang WL, Huang KH, Lan YT, Lin CH, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Li AF. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 2016;7:6201-6220. [PMID: 26701847 DOI: 10.18632/oncotarget.6641] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
72 Sui F, Sun W, Su X, Chen P, Hou P, Shi B, Yang Q. Gender-related differences in the association between concomitant amplification of AIB1 and HER2 and clinical outcomes in glioma patients. Pathol Res Pract 2018;214:1253-9. [PMID: 30153912 DOI: 10.1016/j.prp.2018.06.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ito C, Nishizuka SS, Ishida K, Uesugi N, Sugai T, Tamura G, Koeda K, Sasaki A. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer. J Surg Res. 2017;212:195-204. [PMID: 28550907 DOI: 10.1016/j.jss.2017.01.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
74 Lu M, Zheng ST, Liu Q, Liu T, Gao XP, Ilyar∙Sheyhidin, Lu XM. Role of PIK3CA in cell proliferation, migration and apoptosis in human esophageal squamous cell carcinoma cell line Ecal09. Shijie Huaren Xiaohua Zazhi 2014; 22(32): 4893-4900 [DOI: 10.11569/wcjd.v22.i32.4893] [Reference Citation Analysis]
75 Li H, Chen S, Li H, Cui J, Gao Y, Wu D, Luan S, Qin Y, Zhai T, Liu D, Huo Z. Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis. Oncotarget 2018;9:7651-9. [PMID: 29484141 DOI: 10.18632/oncotarget.23871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Liu R, Qu Y, Chen L, Pu J, Ma S, Zhang X, Yang Q, Shi B, Hou P, Ji M. Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients. Oncotarget 2017;8:92275-88. [PMID: 29190914 DOI: 10.18632/oncotarget.21228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
77 Feng F, Cheng Q, Yang L, Zhang D, Ji S, Zhang Q, Lin Y, Li F, Xiong L, Liu C, Jiang X. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. Oncotarget 2017;8:5349-60. [PMID: 28029662 DOI: 10.18632/oncotarget.14146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
78 Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014;464:367-78. [DOI: 10.1007/s00428-013-1533-y] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
79 Fields AP, Justilien V, Murray NR. The chromosome 3q26 OncCassette: A multigenic driver of human cancer. Adv Biol Regul 2016;60:47-63. [PMID: 26754874 DOI: 10.1016/j.jbior.2015.10.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
80 Jang SH, Kim KJ, Oh MH, Lee JH, Lee HJ, Cho HD, Han SW, Son MW, Lee MS. Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. J Gastric Cancer 2016;16:85-92. [PMID: 27433393 DOI: 10.5230/jgc.2016.16.2.85] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
81 Cui W, Cai Y, Wang W, Liu Z, Wei P, Bi R, Chen W, Sun M, Zhou X. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. J Transl Med. 2014;12:10. [PMID: 24418330 DOI: 10.1186/1479-5876-12-10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
82 Zhang G, Qu Y, Dang S, Yang Q, Shi B, Hou P. Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients. Diagn Pathol. 2013;8:173. [PMID: 24144008 DOI: 10.1186/1746-1596-8-173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
83 Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 2014;111:1102-7. [PMID: 24385586 DOI: 10.1073/pnas.1311909111] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
84 Yu B, Xie J. Identifying therapeutic targets in gastric cancer: the current status and future direction. Acta Biochim Biophys Sin (Shanghai) 2016;48:90-6. [PMID: 26373844 DOI: 10.1093/abbs/gmv084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
85 Joo MK, Park JJ, Chun HJ. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol 2016; 22(19): 4638-4650 [PMID: 27217696 DOI: 10.3748/wjg.v22.i19.4638] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
86 Peczek L, Zuk K, Stec-Michalska K, Medrek M, Nawrot B. The influence of Helicobacter pylori eradication on the expression and methylation status of the FHIT gene in non-cancerous gastric mucosa of dyspeptic patients. J Dig Dis 2015;16:385-94. [PMID: 25943773 DOI: 10.1111/1751-2980.12252] [Reference Citation Analysis]
87 Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 2014;1846:232-237. [PMID: 24858418 DOI: 10.1016/j.bbcan.2014.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
88 Wang J, Shao X, Liu Y, Shi R, Yang B, Xiao J, Liu Y, Qu X, Li Z. Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis. Expert Rev Mol Diagn 2021;:1-10. [PMID: 34196586 DOI: 10.1080/14737159.2021.1946394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]